BioCentury | May 1, 2020
Distillery Therapeutics

A low-density lipoprotein receptor identified as tauopathy target

...DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the low-density lipoprotein receptor LRP1 could treat tauopathies such as...
...frontotemporal dementia and chronic traumatic encephalopathy. In a human neuroglioma cell line, CRISPR-mediated inhibition of LRP1...
...the mechanism by which LRP1 contributes to tau spread and disease. TARGET/MARKER/PATHWAY: Low-density lipoprotein-related protein 1 alpha-2-macroglobulin receptor (LRP1; CD91...
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...brain by binding to LRP1. Consensus figures provided by FactSet. Targets: LRP1 (CD91) - Low-density lipoprotein-related protein 1 alpha-2-macroglobulin receptor...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
BioCentury | Jul 20, 2018
Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
BioCentury | Nov 3, 2017
Product Development

Liver X factor

...spot.” SciBX: Science-Business eXchange (2014) Pencheva, N., et al. “Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
BioCentury | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

...carcinomatosis. Angiochem Inc. , Montreal, Quebec Product: ANG1005 (formerly GRN1005 ) Business: Cancer Molecular target: Low-density lipoprotein-related protein 1 alpha-2-macroglobulin receptor (LRP1) (CD91)...
BioCentury | Jan 5, 2015
Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
BioCentury | Jun 16, 2014
Regulation

Signal crossing

...increase brain penetration of enzymes. EPiC comprises a series of peptides that bind LRP1 ( CD91...
BioCentury | Jun 16, 2014
Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
Items per page:
1 - 10 of 116